Rakesh Arora, HOR, India at Macquarie Capital Securities told CNBC-TV18, "We are recommending to stay away from Wockhardt. The reason is that its two other facilities are going in for FDA inspection in August. It is difficult to predict what will be the outcome given the warning letter and import alert in their third facility."
"So it is better to stay away and wait for clarity on those two facilities because the impact is going to be much sharper, almost 30-40 percent of earnings," Arora said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
